A spin-off from ESPCI Paris, Minos Biosciences SAS aims to become, within 5 years, a leading player in the fast-growing life sciences research market involving very high throughput single cell analysis. Minos Biosciences is developing a unique and revolutionary solution for very high throughput single-cell analysis, which allows a direct coupling between image-based phenotypic analysis and omics analyses obtained by sequencing. The Minos solution combines state-of-the-art microfluidics, molecular biology, imaging and bioinformatics.
The ability to directly correlate physiology to the underlying molecular complexity at single cell resolution is a critical need for life sciences and clinical research not covered by existing technologies. The solution proposed by Minos Biosciences, exploiting technologies initially developed at the ESPCI and exclusively licensed to Minos Biosciences by PSL University, will enable this critical need to be met.
Minos Biosciences has developed a targeted and ambitious roadmap and market penetration strategy, with the commercialization of its first system scheduled for the fall of 2023. Minos Biosciences has assembled a highly skilled operational team, which will be strengthened in the first quarter of 2021. Minos also relies on a group of highly committed scientific founders with highly complementary expertise, and on leading strategic advisors on industrial, marketing and business aspects.